These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33327817)

  • 1. Reduction of immunosuppression for post-transplant lymphoproliferative disorder (PTLD): a single-center experience of allograft survival outcomes.
    Pan K; Franke AJ; Skelton WP; Bishnoi R; Shah C; Dang NH; Alquadan K
    Leuk Lymphoma; 2021 May; 62(5):1123-1128. PubMed ID: 33327817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder.
    Rouphael B; Lankireddy S; Lazaryan A; Kukla A; Ibrahim HN; Matas AJ; Issa N
    Clin Transplant; 2016 Jan; 30(1):60-5. PubMed ID: 26497471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute renal allograft rejection in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder.
    Purighalla R; Shapiro R; Jordan ML; Scantlebury VP; Gritsch HA; Vivas C; Randhawa PS
    Clin Transplant; 1997 Dec; 11(6):574-6. PubMed ID: 9408687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post Transplant Lymphoproliferative Disorder risk factors in children: Analysis of a 23-year single-institutional experience.
    Bosse RC; Franke AJ; Paul Skelton W; Woody LE; Bishnoi R; Wang Y; Bhaduri-McIntosh S; Rajderkar D; Shih R; Dang NH; Slayton WB
    Pediatr Transplant; 2020 Aug; 24(5):e13747. PubMed ID: 32497335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center.
    Cockfield SM; Preiksaitis JK; Jewell LD; Parfrey NA
    Transplantation; 1993 Jul; 56(1):88-96. PubMed ID: 8333073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.
    Taylor E; Jones M; Hourigan MJ; Johnson DW; Gill DS; Isbel N; Hawley CM; Marlton P; Gandhi MK; Campbell SB; Mollee P
    Nephrol Dial Transplant; 2015 Oct; 30(10):1774-9. PubMed ID: 26188340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
    Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
    Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Course of renal allograft function after diagnosis and treatment of post-transplant lymphoproliferative disorders in pediatric kidney transplant recipients.
    Zierhut H; Kanzelmeyer N; Buescher A; Höcker B; Mauz-Körholz C; Tönshoff B; Metzler M; Pohl M; Pape L; Maecker-Kolhoff B
    Pediatr Transplant; 2021 Sep; 25(6):e14042. PubMed ID: 34021949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
    Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
    Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-transplant lymphoproliferative disorder in adult liver transplant recipients: a South American multicenter experience.
    Mendizabal M; Marciano S; dos Santos Schraiber L; Zapata R; Quiros R; Zanotelli ML; Rivas MM; Kusminsky G; Humeres R; Alves de Mattos A; Gadano A; Silva MO
    Clin Transplant; 2013; 27(4):E469-77. PubMed ID: 23758407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postransplant lymphoproliferative disorder localized near the allograft in renal transplantation.
    Kew CE; Lopez-Ben R; Smith JK; Robbin ML; Cook WJ; Gaston RS; Deierhoi MH; Julian BA
    Transplantation; 2000 Mar; 69(5):809-14. PubMed ID: 10755531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-transplant lymphoproliferative disorder.
    Kalinova L; Indrakova J; Bachleda P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Dec; 153(4):251-7. PubMed ID: 20208963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and prognosis of post-transplant lymphoproliferative disorders within renal allograft: Report from the PTLD.Int. Survey.
    Khedmat H; Taheri S
    Ann Transplant; 2010; 15(3):80-6. PubMed ID: 20877272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Clinical Features and Outcome of Pediatric Posttransplant Lymphoproliferative Disorder in Recipients of Small Bowel Allograft Versus Isolated Liver Transplantation.
    Chiou FK; Beath SV; Morland B; Hartley J; van Mourik I; Abdel-Hady M; Kelly DA; Sharif K; Gupte GL
    Transplantation; 2020 Jul; 104(7):1429-1436. PubMed ID: 31651718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Non-Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder.
    Major A; Kamdar M
    Curr Treat Options Oncol; 2018 May; 19(7):33. PubMed ID: 29797086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of plasmacytic hyperplasia arising in a kidney allograft salvaged with immunosuppression reduction alone.
    Harada H; Miura M; Shimoda N; Seki T; Togashi M; Ogawa Y; Takada A; Tahara M; Sato H; Hirano T
    Clin Transplant; 2004; 18 Suppl 11():50-3. PubMed ID: 15191374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S; Zafar MN; Best J; Reddy HK
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival.
    Serre JE; Michonneau D; Bachy E; Noël LH; Dubois V; Suberbielle C; Kreis H; Legendre C; Mamzer-Bruneel MF; Morelon E; Thaunat O
    Kidney Int; 2014 Jan; 85(1):182-90. PubMed ID: 23802193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dysfunction of a kidney allograft with life-threatening results].
    Harendza S; Ahrens M; Schneider A; Pfalzer B; Erbersdobler A; Helmchen U; Feller AC; Stahl RA
    Internist (Berl); 2004 May; 45(5):592-6. PubMed ID: 15014890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.